ABVC BioPharma: zero revenue, $21M of assets, and a pipeline too wide for its cash balance
ABVC looks like a tiny biotech, a licensing company, a CDMO, and a Taiwan real-asset story in the same filing. The first proof gate is whether cash, controls, and partners can catch up to the size of the pipeline.
Open